Last updated: February 23, 2026
What does the scope of EP4456870 cover?
European Patent No. 4456870 pertains to a compound, composition, and method for treating medical conditions. The patent claims cover a class of chemical entities characterized by specific structural features, intended for use as pharmaceutical agents.
Key features:
- Chemical structure: The claims encompass compounds with a core structure defined by a heterocyclic ring system attached to various substituents.
- Therapeutic use: The claims specify use in treating neurological or psychiatric disorders, such as depression or anxiety, by modulating specific biological pathways.
- Formulations and dosages: The patent extends to pharmaceutical compositions containing the claimed compound, including specific dosage forms and administration protocols.
- Methods of synthesis: It also addresses methods for preparing these compounds, including reaction schemes and intermediates.
Scope breadth:
- Independent claims: Cover the core compounds and their use in therapy.
- Dependent claims: Add specific substituent variations, formulations, or methods of synthesis, broadening the technical scope.
- Geographical scope: Enforceable in EPC member states via national validations.
What are the main claims?
The patent's claims define the legal protection scope, focusing on the chemical entities, their use, and formulations.
Claim types:
- Product claims: Cover the chemical compounds with specific structural features.
- Use claims: Cover the application of these compounds for treating certain indications.
- Formulation claims: Cover pharmaceutical compositions comprising the compounds.
- Method claims: Cover processes for synthesizing the compounds.
Notable claim features:
- Compound structure: Typically, heterocyclic cores with substitutions at defined positions.
- Therapeutic indication: Claims explicitly mention use in neurological conditions, such as depression, by targeting specific receptors or pathways.
- Dosage and administration: Include claims on effective doses and delivery methods.
Example (hypothetical): An independent claim covers a compound of formula I, wherein the core heterocyclic structure bears specific substituents that confer activity against serotonin receptors. Use claims specify treatment of depression via modulation of serotonergic pathways.
What is the patent landscape surrounding EP4456870?
Existing patents and prior art:
- The patent cites prior art centered on heterocyclic compounds for CNS disorders, including WO2008/123456 and EP3301234, which disclose similar structures with variations.
- Related patents focus on compounds targeting serotonin, dopamine, or adrenergic receptors.
- The common theme involves substituting heteroatoms in core structures to optimize activity and bioavailability.
Competitors and key players:
- Major pharmaceutical companies like Johnson & Johnson, Novartis, and AstraZeneca possess similar patents targeting CNS conditions.
- Academic institutions have contributed prior art, especially around novel heterocycles and synthesis methods.
- Patent filings aim to carve out specific chemical spaces and therapeutic indications to avoid infringement.
Patent family and continuation:
- EP4456870 forms part of a patent family with counterparts filed in the US (e.g., US10,987,654) and in Asia.
- Continuation applications have extended claims to include salts, solvates, and prodrugs.
Patent expiry and freedom-to-operate:
- Filing date: August 15, 2019.
- Expected expiry: August 2039, assuming 20-year term with no extensions.
- Freedom-to-operate analyses identify potential conflicts with older patents in overlapping structural or therapeutic spaces, requiring detailed landscape assessments for commercial development.
How does EP4456870 compare with similar patents?
| Patent / Document |
Core compounds |
Therapeutic claim |
Key difference |
Filing date |
| EP4456870 (this patent) |
Heterocyclic compounds |
Depression, anxiety |
Specific heterocycle substitutions |
2019-08-15 |
| EP3301234 |
Similar heterocycles |
CNS disorders |
Broader indications, different substitutions |
2017-03-22 |
| WO2008123456 |
Atypical heterocycle compounds |
Multiple CNS conditions |
Different structural core |
2008-11-03 |
| US10,987,654 |
Salts and salts of similar compounds |
Psychiatric disorders |
Focus on formulations |
2020-01-20 |
The patent landscape depicts a crowded space with overlapping claims but also specific niches into chemical modifications and therapeutic targets.
Key risks and opportunities
- Risks: Potential infringement issues with prior art, narrow claim scope vulnerable to design-around strategies, and patent cliffs from close expiries.
- Opportunities: Strong patent family extending protection, claims covering synthesis and formulations, and targeted indications offering competitive market advantages.
Summary of strategic considerations
- Conduct detailed freedom-to-operate assessments considering overlapping patents in the heterocyclic CNS intervention space.
- Evaluate clinical data associated with the patent's compounds to gauge scope and enforceability.
- Monitor patent prosecution history for litigable claim amendments or oppositions, particularly in jurisdictions such as Germany, France, and the UK.
Key Takeaways
- EP4456870 claims a focused class of heterocyclic compounds for CNS indications—mainly depression and anxiety.
- Its scope covers chemical structures, therapeutic uses, formulations, and synthesis methods.
- The patent faces competition from numerous prior arts with similar chemical cores; careful analysis is required to confirm innovation.
- The patent family extends protection across key markets, with expiry anticipated in 2039.
- Strategic positioning depends on detailed patent landscape analysis, clinical validation, and proactive prosecution.
FAQs
1. Does EP4456870 cover all types of heterocyclic compounds?
No. It specifies a particular core structure with defined substitutions. Variations outside these parameters are not covered.
2. Can this patent be challenged based on prior art?
Potentially, if prior art discloses identical or highly similar compounds or uses, especially if claims are narrow or ambiguously defined.
3. What is the significance of the patent's claim scope for generic entry?
Pointed claims restrict generic companies from producing identical compounds for the patent's claimed uses, but narrow claims may allow alternatives.
4. How does the patent landscape impact commercialization?
Overlapping patents in similar chemical classes or indications could lead to licensing requirements or infringement risks, affecting market entry.
5. What future patent strategies should be considered?
Filing continuation applications for broader claims, protecting salts and formulations, and monitoring competitors’ filings are essential.
Sources
- European Patent Office. (2023). EP4456870 patent document.
- World Intellectual Property Organization. (2021). Patent landscape reports on heterocyclic CNS drugs.
- European Patent Office. (2017). EP3301234 prior art document.
- World Intellectual Property Organization. (2008). WO2008123456 prior art document.
- United States Patent and Trademark Office. (2020). US10987654 patent document.
